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Abstract
TDP-43 proteinopathies have been observed in a wide range of neurodegenerative diseases. Mutations in the gene
encoding TDP-43 (i.e., TDP) have been identified in amyotrophic lateral sclerosis (ALS) and in frontotemporal lobe
degeneration associated with motor neuron disease. To study the consequences of TDP mutation in an intact system, we
created transgenic rats expressing normal human TDP or a mutant form of human TDP with a M337V substitution.
Overexpression of mutant, but not normal, TDP caused widespread neurodegeneration that predominantly affected the
motor system. TDP mutation reproduced ALS phenotypes in transgenic rats, as seen by progressive degeneration of motor
neurons and denervation atrophy of skeletal muscles. This robust rat model also recapitulated features of TDP-43
proteinopathies including the formation of TDP-43 inclusions, cytoplasmic localization of phosphorylated TDP-43, and
fragmentation of TDP-43 protein. TDP transgenic rats will be useful for deciphering the mechanisms underlying TDP-43–
related neurodegenerative diseases.
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Introduction
TAR DNA-binding protein (TDP-43) is a highly conserved
ribonucleoprotein that is encoded by the TDP gene and can bind
to RNA, DNA, and proteins [1-3]. In mammals, the primary
transcript of the TDP gene can be alternatively spliced to generate
11 mRNA molecules. The major splice variant is full-length and
encodes TDP-43 [4]. While the functions of this complex molecule
remain largely unknown, ubiquitinated and phosphorylated TDP-
43 accumulates in the nucleus and cytoplasm of affected cells in
sporadic amyotrophic lateral sclerosis (ALS) and frontotemporal
lobe degeneration (FTLD) [5,6]. TDP-43 resides predominately in
the nucleus and its translocation to the cytoplasm appears to be an
early event in the pathological process underlying sporadic ALS
[7]. At the end-stages of sporadic ALS and FTLD, C-terminal
fragments of TDP-43 are remarkably increased in the brain [5,6],
but the full-length protein remains the major species in spinal cord
[8], suggesting that regional differences exist in the metabolism
and pathological mechanisms of TDP-43. Although TDP-43
proteinopathies have been identified in a wide range of
neurodegenerative diseases including sporadic ALS, FTLD,
Alzheimer’s disease, and dementia with Lewy bodies [5–9],
TDP-43 inclusions have not been detected in familial ALS caused
by mutation of the SOD1 and FUS genes [10–13]. These findings
imply that TDP-43 proteinopathy is common to neurodegener-
ative diseases and that divergent pathological processes may
underlie sporadic and familial cases of ALS.
Mutations in the TDP gene segregate with ALS and FTLD
associated with motor neuron disease (FTLD-MND) in geograph-
ically unrelated families [14–18], suggesting that TDP mutation is
pathogenic in a subset of neurodegenerative diseases. Transient
expression of the mutant, but not the normal, human TDP gene
leads to apoptotic death of spinal motor neurons in chicken
embryos [15]. In Drosophila melanogaster, depletion of the TDP
homolog results in deficient locomotor activity and defects at
neuromuscular junctions (NMJs) [19]. Suppression of TDP gene
expression induces cell death in cultured neuroblastoma cells [20].
Previous studies indicate that mutation of the TDP gene is
neurotoxic and that normal TDP-43 is important to cellular
function; however, how mutations in the TDP gene cause
neurodegeneration remains unknown.
To study the consequences of TDP mutation in an intact system,
we expressed a mutant form of the human TDP gene in rats, which
were chosen over mice because they are the preferred animals for
pharmacological studies. Overexpression of a mutant, but not the
normal, human TDP gene caused widespread neurodegeneration,
which predominantly affected the motor system. Transgenic rats
that constitutively or conditionally expressed a mutant form of
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human TDP with a valine-to-methionine substitution at position
337 (M337V) developed similar phenotypes at early ages, the
phenotypes that were characterized by motor neuron degenera-
tion accompanied by astrocyte and microglial activation in the
spinal cord.
Results
Constitutive expression of a mutant, but not the normal,
human TDP gene causes early death in transgenic
founder rats
TDP-43 is widely expressed in mammalian tissues [21]. To
mimic the expression profile of the endogenous TDP gene, we
extracted the minimal human TDP gene (mini TDP gene) from a
BAC clone and discarded the excess flanking sequences. The mini
human TDP transgene contains essential elements for regulating
transgene expression but does not carry unwanted genes into
transgenic rats (Figure 1A). Among all known mutations in the
TDP gene, the M337V substitution is found in geographically
unrelated families and thus is an excellent representative of TDP
gene mutations [15,17]. We introduced the M337V mutation into
the mini TDP transgene using a recombineering technique [22].
Using pronuclear injection, we generated three transgenic
founders (two males: founders 1 and 2; one female: founder 3)
that robustly expressed the miniTDP43M337V transgene
(Figure 1A–1C and 1F). The mutant TDP transgenic founders
were indistinguishable from their nontransgenic littermates at
birth; however, they soon lost mobility and died at postnatal ages.
Founder 3 died at the age of 10 days. Founder 2 showed weakness
in the limbs at the age of 13 days and became paralyzed by the age
of 18 days. Founder 1 showed weakness in a forelimb at the age of
21 days and became paralyzed by the age of 29 days. We
examined founder 1 using immunohistochemistry and observed a
reduction in motor neurons in the ventral horn of the lumbar
spinal cord (Figure 1F). Since none of the mutant TDP
(miniTDP43M337V) transgenic rats survived to sexual maturity,
mutant TDP transgenic lines could not be established. In parallel,
we generated two transgenic founder rats that carried the normal
human TDP transgene (miniTDP43wt), which had an identical
DNA composition as miniTDP43M337V except that it lacked the
M337V mutation (Figure 1A–1E). The miniTDP43wt transgenic
rats expressed human TDP-43 protein at levels comparable to
those detected in the miniTDP43M337V transgenic founder rats
but did not develop paralysis by the age of 200 days. These
findings suggest that the disease phenotypes observed in the
miniTDP43M337V transgenic founder rats result from toxicity of
the TDP gene mutation.
Temporal expression of a mutant human TDP gene in
postnatal rats causes progressive paralysis
Since constitutive expression of a mutant human TDP gene
caused a severe phenotype in transgenic founders, we used a
tetracycline (Tet) regulatory system to express the mutant TDP
transgene in a controlled manner. In this way, we could establish
transgenic rat lines expressing the human TDP transgene with a
pathogenic mutation. The Tet-off system is commonly used in
transgenic studies and is comprised of only two elements— a Tet-
controlled transactivator (tTA) and a tTA-activated promoter
(TRE) [23]. Using pronuclear injection, we established two
transgenic lines (line number corresponds to transgene copy) that
carry 7 or 16 copies of the TRE-TDP-43M337V transgene under
the control of the TRE promoter (Figure 2A). The transcriptional
activator, tTA, is inactive in the presence of the Tet derivative,
Doxycycline (Dox), allowing for inactivation of a TRE promoter-
controlled gene through Dox administration in the bigenic rats
that carry the TRE-TDP-43M337V and the tTA transgenes
(Figure 2A). In the absence of Dox, tTA constantly activates the
TRE-TDP-43M337V transgene, producing an expression pattern
that is indistinguishable from constitutive transgene expression
[24].
Constitutive expression of the miniTDP-43M337V transgene
caused postnatal death in the transgenic founder rats (Figure 1),
suggesting that the mutant TDP gene is highly toxic. To test
whether the severe phenotype observed in the constitutive
transgenic rats could be reproduced in conditional transgenic
rats, we produced the TRE-TDP-43M337V and tTA double
transgenic rats by crossing the TRE-TDP-43M337V transgenic
lines with a tTA transgenic line that expresses the tTA transgene at
levels sufficient to vigorously activate tTA reporter genes [24]. To
obtain a constitutive pattern of transgene expression, we allowed
the TRE-TDP-43M337V transgene to be expressed from early
embryogenesis by withholding Dox treatment. Consistent with
findings in constitutive transgenic rats (Figure 1), expression of the
TRE-TDP-43M337V transgene from early embryonic stages caused
severe phenotypes in the conditional transgenic rats of line 16
(Figure 2B). Transgenic rats of line 16 became paralyzed and died
by postnatal day 20 (P20). The similarity in phenotypes between
the constitutive and conditional transgenic rats indicates that the
observed defects did not result from an insertional mutation.
Expression of the TDP-43M337V transgene from early embryo-
genesis caused early death in transgenic rats, making functional
analysis of this model a challenge. To facilitate analysis of motor
function, we added Dox to the drinking water (50 mg/ml) of
breeding rats to suppress transgene expression during embryonic
development. We then withdrew Dox at 4 days before delivery to
allow for recovery of transgene expression in postnatal rats. As a
result, the transgene was not expressed in newborn pups but was
fully expressed in postnatal rats by P10 (Figure S1). The TRE-
TDP-43M337V transgenic rats of line 16 showed a rapid
progression of disease phenotypes, exhibiting limb weakness by
P20 and paralysis before P35 (Figure 2E). In contrast, the TRE-
TDP-43M337V transgenic rats of line 7 showed a later onset and a
slower progression of similar phenotypes (Figure 2C–2E). Disease
progression in line 7 could be divided into four distinct stages [25]:
the nonsymptomatic stage, disease onset, the paralysis stage, and
the disease end stage. Disease onset was defined as an
unrecoverable reduction in running time on a rotating Rotarod.
The paralysis stage was defined as visible dragging of a limb. The
Author Summary
Amyotrophic lateral sclerosis, a condition also known as
Lou Gehrig’s disease, is characterized by progressive
degeneration of motor neurons, denervation atrophy of
skeletal muscles, and eventual paralysis of affected limbs.
The signature pathology of Lou Gehrig’s disease is the
formation of intracellular inclusions containing phosphor-
ylated TDP-43 protein. Most cases of Lou Gehrig’s disease
do not have a clear cause, while only about 10% of the
cases are caused by mutation of individual genes. Here, we
describe a novel rat model that expresses a mutated form
of the human gene encoding TDP-43 and manifests the
phenotypes and pathological features observed in patients
with Lou Gehrig’s disease. Laboratory rats are the preferred
animals for pharmacological studies. Therefore, this new
rat model will be useful not only for mechanistic study of
Lou Gehrig’s disease, but also for the development of
therapies for this devastating disease.
TDP Transgenic Rat Model
PLoS Genetics | www.plosgenetics.org 2 March 2010 | Volume 6 | Issue 3 | e1000887
disease end stage was defined as paralysis in two or more limbs.
Postnatal rats aged 21 days were subjected to a Rotarod test to
determine disease onset (Figure 2D). Since transgenic rats of line
16 developed early paralysis and had a rapid disease progression,
determining the time of disease onset for this high-copy line was
technically difficult. Transgenic rats of line 16 showed limb
weakness by an age of 20 days and became paralyzed in the legs by
an age of 35 days, with no sexual dimorphism existing in the rate
of disease progression (Figure 2E). In contrast, transgenic rats of
line 7 displayed sexual dimorphism in the time of disease onset and
in the rate of disease progression (Figure 2D and 2E). Sexual
dimorphism in phenotypic onset has also been observed in an ALS
animal model expressing mutant human SOD1 genes [26–29]. The
disease phenotypes observed in the mutant TDP (TRE-TDP-
43M337V) transgenic rats were not observed in normal TDP
transgenic rats (miniTDP-43WT) by an age of 200 days, though
these rats expressed the human TDP transgene at comparable
levels as TRE-TDP-43M337V rats (Figure 2B–2E). An examination
of TRE-TDP-43M337V transgenic offspring revealed that, consis-
tent with findings in miniTDP-43M337V transgenic founders
(Figure 1), the disease phenotypes in these animals were related
to mutation of the TDP gene.
Figure 1. Postnatal death in transgenic founder rats constitutively expressing a mutant human TDP transgene. (A) Schematic diagram
shows the structure of the human TDP transgene extracted from a BAC clone. The M337V mutation was introduced into the TDP transgene construct
using a recombineering technique. (B) PCR identified transgenic founders carrying the normal (WT) or mutant (TDP43M337V) human TDP gene. NT:
nontransgenic littermate. (C) Immunoblotting detected a robust expression of the TDP transgene in the forebrain of TDP43M337V transgenic founders
and TDP43WT transgenic offspring (first generation). Membranes were probed with an antibody against human TDP-43 (generated in-house) and then
with an antibody against GAPDH. NT: a nontransgenic littermate. (D–F) Immunohistochemistry revealed that human TDP-43 was expressed in the
normal (E) and mutant (F) human TDP transgenic rats, but not in nontransgenic littermates (D) at the age of 29 days. Transverse sections through the
L4 spinal cord were stained for human TDP-43 immunoreactivity and then counterstained with haematoxylin. Micrographs show the ventral horn of
the lumbar spinal cord.
doi:10.1371/journal.pgen.1000887.g001
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Axon terminals are the primary targets of degeneration
caused by mutation of the TDP gene
Anatomical analysis revealed that motor neurons in the spinal
cord robustly expressed the human TDP transgene (Figure 3A–
3C). The number of spinal motor neurons was significantly
reduced in mutant TDP transgenic rats but not in normal TDP
transgenic rats (Figure 3D–3F and 3I), although the mutant and
normal TDP transgenic rats expressed human TDP-43 at
comparable levels (Figure 2B). Large-caliber neurons were
preferentially affected in mutant rats at the end stages of disease
(Figure 3D–3F and 3L). During the paralysis stage, degenerating
axons were clearly visible in the ventral (Figure 3G–3I and 3M)
and dorsal roots (Figure S2), with motor axons of the corticospinal
track also being affected (Figure S3). Confocal microscopy
revealed that denervation of synaptic endplates in skeletal muscle
occurred at disease onset (Figure 4B and 4D) and worsened at the
end stage of disease (Figure 4C and 4D). Electron microscopy
confirmed that, in the mutant transgenic rats, degeneration of
motor neuron axons occurred at disease onset (Figure 4F and 4G);
however, no loss of motor neurons was detected in the mutant
TDP transgenic rats at this time. These findings suggest that axon
terminals are the primary targets of degeneration associated with
pathogenic mutation of TDP. In the mutant TDP transgenic rats,
denervation of skeletal muscle fibers was confirmed by electromy-
ography, which detected frequent fibrillation potentials—a
characteristic of muscle denervation and regeneration
Figure 2. Progressive paralysis in transgenic rats conditionally expressing a mutant human TDP gene. (A) Schematic diagram shows the
structure of the inducible mutant TDP transgene (TRE-TDP-43M337V). Expression of the mutant TDP transgene depends on tTA activation and can be
suppressed by Dox, which binds to tTA and renders it inactive. (B) Immunoblotting detected a robust expression of the transgene in the spinal cord
of P20 rats. Membranes were probed sequentially with antibodies against human TDP-43 (generated in-house), human and rat TDP-43 (ProteinTech),
and rat GAPDH. M337V: transgenic rats carrying the conditional mutant TDP (TRE-TDP-43M337V) and CAG-tTA transgenes; WT: transgenic rat carrying
the mini normal human TDP transgene (miniTDP-43WT); NT: nontransgenic littermate of the WT transgenic rat; *, a weak nonspecific band. (C) Photo
of a mutant TDP transgenic rat (line 7) paralyzed at P40. (D) Graphs show the probability of disease onset, defined as an unrecoverable reduction in
running time on a Rotarod. Disease onset for line 16 was not plotted, since these animals experienced early paralysis with rapid progression and
accurate definition of disease onset was technically difficult. (E) Survival analysis revealed that lifespan was remarkably reduced in the mutant TDP
transgenic rats. Rats were euthanized and counted as dead when two or more legs became paralyzed. Male and female rats of line 16 were combined
as one group because disease progression between each gender was indistinguishable. Definition of symbols in (D,E): &, normal TDP transgenic rats
carrying the miniTDP-43WT transgene (line 4; n = 9); N and #, mutant male (N, n = 10) and female (#, n = 12) transgenic rats carrying the TRE-TDP-
43M337V (line 7) and CAGtTA transgenes; ¤, mutant TDP transgenic rats carrying the TRE-TDP-43M337V (line 16) and the CAGtTA transgenes (n = 14). All
breeding female rats were given Dox in drinking water (50 mg/ml) until 4 days before delivery.
doi:10.1371/journal.pgen.1000887.g002
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(Figure 4E). As results of denervation, groups of skeletal muscles
were atrophied (Figure 4H and 4I). These pathological changes
were correlated with progressive paralysis in the mutant transgenic
rats (Figure 2C–2E).
Neurodegeneration is accompanied by glial reactivity
Silver staining revealed that, in mutant TDP transgenic rats,
spinal motor neurons degenerated during end-stage disease
(Figure 5A and 5B). A previous study showed that transient
expression of the mutant, but not the normal human TDP gene,
causes apoptotic death in the spinal cord of chicken embryos [15].
Consistent with the finding from this transient transfection study
[15], motor neurons in the spinal cord underwent apoptosis in
paralyzed transgenic rats (Figure 5C and 5D). Studies of mutant
SOD1 mice suggest that glial cells play an important role in ALS
pathogenesis [28,30–33]. Therefore, we examined glial reactions
in our paralyzed rats. We found that astrocytes and microglia were
increased around the motor neurons in the spinal cord (Figure 6A–
6D). The finding suggests that a glial reaction occurs in response to
motor neuron degeneration.
Neurodegeneration is not restricted to motor neurons at
end stages of disease
TDP-43 inclusions are found in the brain and spinal cord of
patients with sporadic ALS, FTLD, Alzheimer’s disease, or
dementia with Lewy bodies [5–9], suggesting that TDP-43
proteinopathies are common to neurodegenerative diseases.
Pathogenic mutations in the TDP gene have been identified not
only in ALS, but also in FTLD-MND [14–18]. Degeneration
associated with mutations in the TDP gene may not be restricted to
motor neurons. Indeed, silver staining revealed that neurodegen-
eration occurred in the cortex, hippocampus, and cerebellum of
mutant transgenic rats with end stages of disease (Figure 7A–7F)
but not in those with earlier stages of disease (Figure 2D and data
not shown). Nevertheless, degenerating neurons were not detected
in the substantia nigra of paralyzed rats (data not shown), despite
the fact that transient overexpression of the normal human TDP
gene in rats has been shown to induce a loss of dopaminergic
neurons in this brain region [34]. Neuropathological findings were
correlated with phenotypic expression in mutant TDP transgenic
rats (Figure 2, Figure 3, Figure 4). Toxicity of the pathogenic TDP
gene mutation was not restricted to motor neurons, though these
neurons were affected by the mutation to a greater degree than all
the other neuron types examined.
Phosphorylated TDP accumulates in affected cells in TDP
transgenic rats
Phosphorylated TDP-43 inclusions are a signature pathological
feature of sporadic ALS and FTLD [5,6,35–37]. To detect
phosphorylated TDP-43 inclusions in our transgenic rats, we
tested a polyclonal antibody specific to phosphorylated TDP-43 on
brain sections of FTLD patients and TDP transgenic rats. This
phospho-TDP-43 antibody detected cytoplasmic accumulation of
phosphorylated TDP-43 in FTLD patients, but not in control
subjects (Figure 8A). Similarly, phosphorylated TDP-43 was
diffusely distributed in affected neurons in transgenic rats
expressing the mutant or normal human TDP transgene
(Figure 8D). We generated a polyclonal antibody recognizing
Figure 3. Neuronal death and axonal damage in transgenic rats expressing a mutant human TDP gene. (A–C) Transverse sections of
lumbar spinal cord were immunostained for human TDP-43 (red) and ChAT (green). Scale bars: 30 mm. (D–F) Cresyl violet staining revealed motor
neurons in the ventral horn of L3 spinal segments. Scale bars: 100 mm. (G–I) Toluidine blue staining shows axons of L3 ventral roots. (J,K) Transmission
electron microscopy (EM) shows the structure of axons in the L3 ventral roots. Degenerating axons were shrunken and had collapsed myelin (arrows).
Scale bars: 5 mm. (L) The number of large neurons (.25 mm in diameter) in the ventral horn of L3 spinal segments was estimated by stereological cell
counting. Data are expressed as the mean 6 SD (n = 9–15). *p,0.05. (M) Axons of L3 ventral roots were visualized by EM, and 60 axons (.4 mm in
diameter) of each animal were examined for integrity. Data are expressed as mean 6 SD (n = 8 or 9). *p,0.01. Tissues were collected from paralyzed
transgenic rats of line 7 (age: 4567 days) conditionally expressing the mutant human TDP gene (M337V: C, F, I, K, L, and M), age-matched
nontransgenic littermates (NT: A, D, G, L, and M), and age-matched transgenic rats constitutively expressing the normal human mini TDP gene (WT: B,
E, H, J, L, and M).
doi:10.1371/journal.pgen.1000887.g003
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both phosphorylated and non-phosphorylated human TDP-43
(Figure 1C–1F) and detected a robust expression of the human
TDP transgene in transgenic rats (Figure 8B and 8C). TDP-43 was
diffusely distributed in the nucleus and cytoplasm of cells within
transgenic rats (Figure 8). However, TDP-43 inclusions were
detected rarely, being present only in the cortex (Figure 8B) and
not in the spinal cord (Figure 8C) of transgenic animals.
Immunohistochemistry revealed that typical ubiquitin-positive
inclusions were not present in the spinal cords of normal or
mutant TDP transgenic rats, though the intensity of ubiquitin
immunostaining was greater in these animals than in nontrans-
genic rats (Figure S4). Since TDP-43 inclusions were rare in
transgenic rats, even at end-stage disease, we further examined
TDP-43 ubiquitination using immunoprecipitation combined
with immunoblotting analysis. Ubiquitinated TDP-43 was detect-
ed in the mutant TDP transgenic rats (Figure S4). Immunoblotting
revealed that a small amount of TDP-43 fragments (less than
43 kDa) was present in TDP transgenic rats (Figure 2B and Figure
S5). TDP-43 fragments were detected in urea tissue extracts
from rats at the paralysis stage, but not in extracts from those
at disease onset (Figure S5). The finding suggests that the
solubility of the small TDP-43 fragment is reduced as the disease
progresses.
Discussion
Expression of the human TDP gene containing a M337V
substitution reproduced the phenotypes of ALS in rats. That is,
these animals exhibited progressive degeneration of motor neurons
and denervation atrophy of skeletal muscles. In this transgenic rat
model, neurodegeneration was not restricted to motor neurons
and could be seen in other types of neurons including cortical
neurons, hippocampal neurons, and cerebellar neurons. However,
TDP mutation affected motor neurons earlier and more severely
than other neurons in the central nervous system (CNS). This
robust rat model also recapitulated features of TDP-43 proteino-
pathies, including the formation of TDP-43 inclusions, cytoplas-
mic localization of phosphorylated TDP-43, and fragmentation of
TDP-43.
While our transgenic rat model developed the phenotypes of
ALS, it displayed degeneration of CNS neurons other than motor
neurons at the end stages of the disease. Our findings in mutant
TDP transgenic rats do not necessarily contradict observations in
ALS patients. ALS is traditionally thought to affect only motor
neurons, but recent studies showed that neurons other than motor
neurons also degenerate in ALS [38]. This point is strikingly
illustrated by the observation in some ALS patients who live with
Figure 4. Denervation atrophy of skeletal muscle in transgenic rats expressing a mutant human TDP gene. (A–C) The neuromuscular
junction (NMJ) in the gastrocnemius muscles was examined by confocal microscopy to reconstruct the focal structure. Compared to the NMJ in a
control rat (A), the NMJ in TRE-TDP-43M337V transgenic rats (line 7) was partially denervated at disease onset (B) and severely denervated at disease
end stages (C). Axon terminals were visualized by immunostaining for synaptophysin and neurofilament (NF), while postsynaptic nicotinic receptors
were visualized with Alexa fluor 555-conjugated a-bungarotoxin. (D) Quantification of NMJ denervation in nontransgenic control rats (NT) and TRE-
TDP-43M337V transgenic rats at disease onset or the paralysis stage. Twenty NMJs were examined for each animal (n = 4 or 5). (E) Electromyography of
the gastrocnemius muscles revealed that frequent fibrillation potentials (arrows) were present in paralyzed TRE-TDP-43M337V transgenic rats (M337V),
but not in a nontransgenic littermate (NT). (F,G) EM revealed that intramuscular axons underwent degeneration in a mutant transgenic rat (line 7, age:
32 days) at disease onset (G), but not in an age-matched nontransgenic littermate (F). The arrow indicates a cluster of aggregates that accumulated in
the axon of a mutant rat (G). SM: skeletal muscle; a: axon; N: the nucleus of a Schwann cell. Scale bars: 2 mm. (H,I) Group atrophy of the gastrocnemius
muscle in paralyzed TRE-TDP-43M337V transgenic rats was detected by H&E staining (H, arrows) and by histochemistry for nonspecific esterase (I).
doi:10.1371/journal.pgen.1000887.g004
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the disease much longer than the average disease duration
[38–40]. Moreover, some ALS and FTLD cases share symptoms
and pathological characteristics [41]. Although mutations of the
TDP gene are primarily associated with ALS [14–17], a recent
study found that a novel mutation in the TDP gene is associated
with FTLD-MND [18], suggesting that the toxicity (if any) of the
TDP gene mutation is not restricted to motor neurons [18].
Further studies are warranted to ascertain whether a correlation
exists between the pathological changes induced by TDP mutation
and TDP-43 proteinopathies observed in sporadic ALS and
FTLD. The fact that TDP-43 proteinopathy is observed in a wide
range of neurodegenerative diseases suggests that mutations in the
TDP gene are generally neurotoxic [5,6,9,42–45]. Neurodegener-
ative diseases may share common pathological mechanisms, with a
certain subgroup of neurons being predominantly affected under
each disease condition. Our mutant TDP transgenic rat is a robust
model of neurodegeneration caused by mutation of the TDP gene.
Many features of TDP-43 proteinopathies were reproduced in
our TDP transgenic rats. Redistribution, phosphorylation, and
aggregation of TDP-43 are all hallmarks of sporadic FTLD and
ALS [5,44,45]. A recent clinical study showed that TDP-43
redistribution appears to be an early event in TDP-43 proteino-
pathy [7], suggesting that TDP-43 redistribution underlies the
pathogenesis of neurodegeneration. Our results showed that
phosphorylated TDP-43 was diffusely distributed in the cytoplasm
and nucleus of affected cells in paralyzed mutant TDP transgenic
rats as well as in non-paralyzed, normal TDP transgenic rats. The
presence of phosphorylated TDP-43 in normal TDP transgenic
rats does not exclude the possibility that TDP-43 phosphorylation
contributes to pathogenesis induced by TDP mutation. Specifical-
ly, TDP mutation may impart toxicity by enhancing the normal
functions of the gene. For example, mutation of the LRRK2 gene
causes Parkinson’s disease by enhancing (at least partially) the
kinase activity of LRRK2 [46,47]. Gene mutations can be
classified into three types based on their effect on protein function:
gain of function, loss of function, and dominant negative effect.
Pathogenic mutation of the TDP gene may cause disease through
any one of these three effects on protein function. Resolving the
nature of the TDP gene mutation will require a more sophisticated
model such as a knockin mouse. TDP-43 inclusions and
Figure 5. Degeneration of motor neurons in paralyzed mutant TDP transgenic rats. (A,B) Bielschowski silver staining revealed degenerating
neurons in the lumbar spinal cord of a paralyzed TRE-TDP-43M337V transgenic rat (line 7) (B), but not in the spinal cord of a nontransgenic littermate
(A). (C,D) TUNEL staining shows motor neurons in the spinal cord undergoing apoptosis (D: arrow) in a paralyzed TRE-TDP-43M337V transgenic rat ( line
7) (D), but not in its nontransgenic littermate (C). Transverse sections of the L3 spinal segment were stained with ChAT antibody to visualize motor
neurons and were labeled using a TUNEL staining kit to visualize apoptosis.
doi:10.1371/journal.pgen.1000887.g005
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fragmentation were rarely observed and were present only at end-
stage disease, suggesting that these pathologies may be conse-
quence of, rather than a cause of, neurodegeneration in TDP
transgenic rats. C-terminal truncated products of TDP-43 are
thought to result from caspase cleavage of full-length TDP-43
[48]. Accordingly, C-terminal fragmentation of TDP-43 is likely a
consequence, instead of a cause, of neurodegeneration because
caspase activation is a terminal feature of cell death. In addition,
we cannot exclude the possibility that overexpression of the TDP
transgene interferes with rat development, since the mutant TDP
transgenic rats died at postnatal ages.
Typical ALS has a late onset and rapidly progresses
[12,13,17,29,49–51]. In contrast, mutant TDP transgenic rats
developed paralysis at early ages, with the paralysis being similar
to that seen in ALS. Early onset of disease phenotypes in our rat
model likely results from toxicity of the TDP gene mutation, as
Figure 6. Activation of glial cells in paralyzed mutant TDP transgenic rats. (A,B) Double immunofluorescence staining shows an
accumulation of astrocytes around motor neurons in a paralyzed TRE-TDP-43M337V transgenic rat (line 7) (B), but not in a nontransgenic littermate (A).
(C,D) Double immunofluorescence staining shows an activation of microglial cells in a paralyzed TRE-TDP-43M337V transgenic rat (line 7) (D), but not in
a nontransgenic littermate (C). Transverse sections of the L3 spinal cord were immunostained for ChAT (red; motor neuron marker), GFAP (green;
astrocyte marker), or cd68 (green; microglia and macrophage marker).
doi:10.1371/journal.pgen.1000887.g006
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evidenced by the following three findings. First, paralysis and
lethality were observed in the mutant miniTDP43M337V transgenic
founders, but not in the normal miniTDP43WT transgenic
founders. Second, paralysis and neurodegeneration were observed
in the inducible mutant TDP transgenic rats, but not in offspring of
the constitutive normal TDP transgenic rats, despite the fact that
both lines exhibited comparable expression of the human TDP
transgenes. Third, similar phenotypes were observed in the
constitutive mutant TDP transgenic founders and in the inducible
mutant TDP transgenic offspring. One transgenic founder rat
carried only six copies of the mini mutant TDP transgene and
developed paralysis in postnatal age. The copy number of the
mutant TDP transgene that is required for phenotypic expression
in transgenic rats is much lower than the copy threshold of mutant
SOD1 transgenes [52,53]. To activate the inducible mutant TDP
transgene, we used a low-copy tTA transgenic line that carries only
two copies of the tTA transgene [24]. Therefore, expression levels
of the TDP transgene in the inducible transgenic rats were
comparable to those in the constitutive normal TDP transgenic
rats. Transgenic rats expressing the mutant TDP gene displayed a
wider range of neurodegeneration than transgenic rodents
expressing mutant SOD1 genes [29,52–54], with neurodegenera-
tion predominantly affecting the motor system. Such unrestricted
toxicity of the TDP gene mutation may lead to an early onset of
the disease. In some aspects, phenotypes observed in our
transgenic rats are similar to those detected in transgenic mice
that express the human TDP gene with a A315T substitution [55].
In these rodent models, both upper and lower motor neurons are
affected and TDP-43 inclusions are rare. However, our rat model
developed paralysis at postnatal ages and experienced a rapid
disease progression, while the mutant TDP transgenic mice
develop disease phenotypes during middle age and have varying
disease durations [55]. Different mutations in the TDP gene and
different animal species may contribute to phenotypic variation
between the rat and mouse models.
Our findings in TDP transgenic rats indicate that mutation of
the TDP gene is highly toxic in rodents, though the nature of the
pathogenic mutation in the TDP gene remains to be resolved.
Figure 7. Degeneration of non-motor neurons in paralyzed mutant TDP transgenic rats. (A–F) FD silver staining shows degeneration of
non-motor neurons in paralyzed tTA/TRE-TDP-43M337V bigenic rats (line 7; age: 45 days) (B,D,F), but not in a tTA transgenic littermate (A,B,C).
Degenerating neurons were outlined by deposits of silver particles (arrows). Scale bars: 20 mm.
doi:10.1371/journal.pgen.1000887.g007
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Since deletion of the TDP gene in Drosophila causes defects at NMJs
[19], the possibility that the TDP gene mutation produces a
dominant-negative effect cannot be excluded. Although the nature
of TDP gene mutation will need to be determined using a more
sophisticated model, our TDP transgenic rats will be useful for
mechanistic study of TDP-43-related neurodegenerative diseases.
Figure 8. Phosphorylation and cytoplasmic localization of TDP-43 in FTLD patients and in TDP transgenic rats. (A)
Immunohistochemistry revealed phosphorylation and cytoplasmic localization of TDP-43 (arrows) in the brains of FTLD patients, but not in control
subjects. Paraffin-embedded sections were stained with a polyclonal antibody against TDP-43 phosphorylated at aa409/410. (B,C) Immunostaining
revealed that human TDP-43 was present in both the nucleus and cytoplasm of cells from the mutant (M337V: line 7) and normal (WT) TDP transgenic
rats, but not in the cells of a nontransgenic rat (NT). TDP-43 inclusions (arrow) were rarely detected, being present in only the cortex of paralyzed
M337V transgenic rats. Cryopreserved sections of the rat brain and spinal cord were stained with a polyclonal antibody specific to human TDP-43. (D)
Immunostaining shows a cytoplasmic accumulation of phosphorylated TDP-43 in mutant (M337V) and normal (WT) TDP transgenic rats. A weak
signal for phosphorylated TDP-43 was also detected in the nuclei of cells from a nontransgenic rat (NT). Cryopreserved sections of the spinal cord
were stained with a polyclonal antibody against TDP-43 phosphorylated at aa409/410. All scale bars: 20 mm.
doi:10.1371/journal.pgen.1000887.g008
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Materials and Methods
Ethics statement
Animal use followed NIH guidelines. The animal use protocol
was approved by the Institutional Animal Care and Use
Committees (IACUC) at Thomas Jefferson University. The
Committee for Oversight of Research Involving the Dead at the
University of Pittsburgh School of Medicine approved the use of
human tissue from the University of Pittsburgh ALS Tissue Bank.
Age-matched tissue sections from two FTLD and two non-
neurological disease controls were used for the study.
Transgene constructs
The 22-kb mini human TDP gene was extracted from a BAC
clone (RP11-829B14), and a M337V substitution was introduced
into the mini TDP gene by homologous recombination in
Escherichia coli [22]. The normal and mutant mini TDP transgenes
were linearized by restriction digestion, purified from agarose gels,
and then used to produce transgenic rats through microinjection.
To generate Tet-regulatable TDP transgenic rats, we PCR-
amplified the human TDP-43 ORF from a human brain cDNA
pool (Invitrogen) and generated a mutant carrying the M337V
substitution using site-directed mutagenesis (Stratagene). The
mutated human TDP-43 cDNA gene was inserted downstream
of a tTA-dependent promoter that was constructed by fusing seven
tetracycline-responsive elements (TRE) with a minimal cytomeg-
alovirus promoter (TRE-miniCMV). To enhance gene splicing
and expression, we inserted the first intron of the human ubiquitin
C gene between the TRE-miniCMV promoter and the TDP-43
ORF [24].
Transgenic animal production
Linearized miniTDP43 and TRE-TDP43 transgenes were
injected into the pronuclei of fertilized eggs of Sprague-Dawley
rats. The injected eggs were then transplanted into pseudopreg-
nant females for embryonic development [56]. Transgenic
founders carrying miniTDP-43 transgenes were analyzed for
disease phenotypes. Transgenic founders carrying TRE-TDP-43
transgenes were crossed with CAG-tTA transgenic rats to produce
double transgenic offspring, which were analyzed for transgene
expression and disease phenotypes. The TDP transgenic rats were
identified by PCR amplification of the human TDP gene using the
following primer pair: 59-TGCGGGAGTTCTTCTCTCAG
(forward) and 59-AGCCACCTGGATTACCACCA (reverse).
The copy number of the transgene was determined by quantitative
PCR using two primer pairs. The first primer pair was designed to
amplify a DNA fragment of the same composition from both the
human and the rat TDP gene: 59-TGAGCCCATTGAAATAC-
CATC-39 and 59-TACACTGAGACACTGGATTC. The second
primer pair was designed to amplify the rat prolactin gene as an
internal control: 59-CCTCTATGAACGAAACCCAC-39 and 59-
CTTCCGGCTAATCCA CAATG-39.
Antibody production
A rabbit polyclonal antibody was produced by Genemed
Company. Rabbits were immunized with the synthetic peptide,
(N-terminal)-EDELREFFSQYGDVM. Antiserum was then affin-
ity-purified using a peptide-conjugated column (Pierce).
Immunohistochemistry
Under deep anesthesia, animals were transcardially perfused
with 1X PBS (pH 7.4) and then with 4% paraformaldehyde (PFA)
dissolved in 1X PBS buffer. The brain, spinal cord, and
gastrocnemius muscle of perfused animals were collected and
further fixed in the same fixative overnight. Some tissue blocks
were embedded in paraffin and sectioned into 10 mm-thick slices.
Paraffin-embedded sections were treated with 10 mM sodium
citrate buffer (pH 6.0) to retrieve antigens for immunostaining.
Paraffin-embedded coronal sections of the brain and transverse
sections of the spinal cord were deparaffinized and immunostained
with human TDP-43-specific antibody (1:1,000; made in house) or
a phospho-TDP-43-specific antibody (1:1,000; COSMO Bio Co.,
TIP-PTD-P02). Immunostaining was visualized using an ABC kit
in combination with diaminobenzidine (Vector). The immuno-
stained sections were lightly counterstained with hematoxylin to
display nuclei. After antigen retrieval, paraffin-embedded sections
of the lumbar spinal cord were immunostained for human TDP-
43 (1:300) and ChAT (goat antiserum; Millipore). Immunofluo-
rescence staining for human TDP-43 (red) and ChAT (green) was
visualized using a Nikon fluorescence microscope, and images
were acquired using a Nikon digital camera. Paraffin-embedded
sections of the gastrocnemius muscle were stained with hematox-
ylin and eosin (H&E) to visualize tissue structures.
For NMJ detection, gastrocnemius muscles were fixed in 4%
PFA for 2 h and sectioned on a cryostat into 100 mm-thick
sections. Serial sections of the muscles were incubated with a-
bungarotoxin (Invitrogen) for 30 min, washed in PBS three times,
incubated overnight with mouse monoclonal antibodies to
neurofilament (Sigma) and synaptophysin (Millipore), and then
incubated for 1 h with a secondary antibody (FITC goat anti-
mouse IgG1; Jackson Immunology).
For detection of apoptotic cells and glial cells, 4% PFA-fixed
lumbar spinal cords were cut into three sets of 10 mm-thick serial
sections on a cryostat. Every first section was incubated with
TUNEL staining reagent (Millipore) and goat anti-ChAT
antibody. Every second section was incubated with the ChAT
antibody and mouse anti-GFAP. Every third section was
incubated with the ChAT antibody and mouse anti-CD68
antibody. Sections were then incubated with appropriately labeled
secondary antibodies. The antibodies were purchased from
Millipore. Images were captured using a Zeiss LSM510 META
confocal system. The NMJ was reconstructed using z-stack
projections produced from serial scanning every 1 mm.
Esterase histochemistry
Fresh gastrocnemius muscle was snap-frozen in liquid nitrogen
and cut into 12 mm-thick sections on a cryostat. Nonspecific
esterase activity was detected using the a-napthyl acetate protocol.
Denervated muscle fibers were stained a red-brown color, with
normal fibers displaying a yellow-to-brown color.
Silver staining
Degenerating neurons were visualized using the Bielschowski
silver-staining method as well as the FD NeuroSilver kit (FD
Neurotechnologies, Baltimore, MD). For the Bielschowski silver
method, paraffin-embedded spinal cord was transversely cut into
10 mm-thick sections. For staining using the FD NeuroSilver kit,
40 mm-thick coronal sections were obtained by slicing through the
forebrain and cerebellum using a cryostat and then stained per the
manufacturer’s instructions.
Toluidine blue staining and electron microscopy
Rats were anesthetized and perfused with a mixture of 4% PFA
and 2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). The
L3 and L4 ventral and dorsal roots were removed and post-fixed
in the same fixative at 4uC overnight. The roots were then further
fixed in 1% osmium tetroxide in 0.1 M phosphate buffer (pH 7.4)
for 1 h. The well-fixed tissues were dehydrated in graded ethanol
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and embedded in Epon 812 (Electron Microscopic Sciences, Fort
Washington, PA). Thin sections (80 nm) were then stained with
uranyl acetate and lead citrate for observation under a
transmission electron microscope (Hitachi H7500-I). For toluidine
staining, roots were transversely cut into 1 mm-thick sections.
Axons in the nerve roots were examined in the semi-thin sections
under a light microscope (Olympus AX70).
Cresyl violet staining and stereological cell counting
A 1-mm central segment of the L3 spinal cord was cut into 30-
mm thick sections using a cryostat. Every third section was stained
with cresyl violet and mounted in sequential order (rostral-caudal).
Neurons with a diameter larger than 25 mm were counted in the
ventral horns on both sides. The number of targeted neurons was
estimated using a fractionator-based unbiased stereology software
program (Stereologer), which was run on a PC computer that was
attached to a Nikon 80i microscope with a motorized XYZ stage
(Prior). At low magnification (40x), the targeting area was outlined,
and a random sampling grid was created. At 10006magnification,
an optical dissector probe was randomly generated by the program
in the designated area. The presence of clearly definable neurons
was noted according to defined inclusion and exclusion limits of
the dissector. This process was repeated on all selected sections.
The total number of defined neurons was calculated by the
software based on values obtained from random counts.
Electromyography
Animals were anesthetized during electromyography (EMG)
examination. The fibrillation potential of the gastrocnemius
muscle was recorded with an EMG instrument (CMS6600;
COTEC Inc.) using a 27-gauge monopolar needle electrode and
a 29-gauge reference needle electrode. During recording, a sub-
dermal ground electrode was placed in the forelimb. Spontaneous
electrical activity of selected skeletal muscle was recorded for
2 min.
Statistical analysis
The number of defined neurons in the ventral horn was
compared between groups of transgenic rats. The difference in the
number of neurons was analyzed using an unpaired t test. The null
hypothesis was rejected at the 0.05 level.
Supporting Information
Figure S1 Recovery of TDP transgene expression after Dox
withdrawal. Breeding rats of TRE-TDP-43M337V transgenic line
16 were constantly given Dox in drinking water (50 ug/ml) and
the pregnant female rats were deprived of Dox four days before
delivery. Forebrain of the offspring doubly transgenic for the tTA
and the TRE-TDP-43M337V was dissected at varying ages.
Western blotting detected a robust expression of the TDP
transgene in the offspring by age of 5 days when a human TDP-
43-specific antibody was used to detect TDP-43 immunoreactivity.
Each lane was loaded with 20 mg of total protein in brain lysate.
Immunoreactivity of GAPDH was detected as an internal control
for equal loading.
Found at: doi:10.1371/journal.pgen.1000887.s001 (0.59 MB TIF)
Figure S2 Axons of dorsal root affected in the TRE-TDP-
43M337V transgenic rats at paralysis stage. (A,B) Toluidine blue
staining shows axons of the L3 dorsal roots taken from the tTA/
TRE-TDP-43M337V double (B) or a age-matched tTA single (A)
transgenic rat. (C,D) EM shows axons in the dorsal root of the
tTA/TRE-TDP-43M337V double (D) or a age-matched tTA single
(C) transgenic rat. The mutant rat was terminated when its two
legs paralyzed at the age of 45 days. L3 nerve root was dissected
for histology. Affected axon was shrunk with collapsed myelin
(arrow). Scale bars: 2 mm.
Found at: doi:10.1371/journal.pgen.1000887.s002 (9.52 MB TIF)
Figure S3 Degeneration of dorsal corticospinal tract in the
TRE-TDP-43M337V transgenic rats at paralysis stage. (A,B)
Toluidine blue staining revealed degeneration of motor axons in
the dorsal corticospinal track of the tTA/TRE-TDP-43M337V
double transgenic rat (B), but not in its tTA single transgenic
littermate (A). Low cervical spinal cord was dissected from a
paralyzed TRE-TDP-43M337V transgenic rat or its tTA transgenic
littermate. Arrows point to some dilated axons in the dorsal
corticospinal track of spinal cord.
Found at: doi:10.1371/journal.pgen.1000887.s003 (8.97 MB TIF)
Figure S4 Ubiquitination of TDP-43 in TDP transgenic rats.
(A–C) Micrographs of spinal ventral horns show ubiquitin
Immunohistochemistry on transverse sections of L3 spinal cords
taken from an age-matched nontransgenic rat (A), a miniTDP-
43WT transgenic rat of line 4 (B), or a paralyzed TRE-TDP-
43M337V transgenic rat of line 7 (C). Tissue sections were lightly
counterstained with haematoxylin to show cell nuclei. Note no
typical ubiquitin-positive inclusion in the wildtype and mutant
TDP transgenic rats though the intensity of ubiquitin immuno-
staining was relatively enhanced in TDP transgenic rats (B,C)
compared to nontransgenic control (A). (D,E) Immunoprecipita-
tion in combination with immunoblotting revealed ubiquitination
of TDP-43 (D), but not FUS (E), in the mutant TDP transgenic rats
with paralysis. Urea extracts of rat’s brain were immunoprecip-
itated with antibodies to TDP-43 or FUS and the precipitants
were further analyzed by immunoblotting for ubiquitin
(MAB1510: Millipore) and TDP-43 or FUS immunoreactivity.
Found at: doi:10.1371/journal.pgen.1000887.s004 (8.94 MB TIF)
Figure S5 Fragmentation of TDP-43 in TDP transgenic rats
with end-stage disease. Immunoblotting with an antibody to the C-
terminal of TDP-43 detected fragments of TDP-43 in the mutant
transgenic rats at paralysis stage (P), but not at disease onset (O).
SC: spinal cord. Urea extracts of rat’s tissues were resolved on
12% SDS-PAGE and transferred onto membrane. The mem-
brane was first probed with the TDP-43 antibody and subse-
quently probed with a GAPDH antibody.
Found at: doi:10.1371/journal.pgen.1000887.s005 (0.62 MB TIF)
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